Format

Send to

Choose Destination
Ther Innov Regul Sci. 2015 Jan;49(1):108-115. Epub 2014 Jun 27.

Maximal Usage Trial: An Overview of the Design of Systemic Bioavailability Trial for Topical Dermatological Products.

Author information

1
US Food and Drug Administration, Silver Spring, MD, USA.

Abstract

Dermatologic diseases can present in varying forms and severity, ranging from the individual lesion and up to almost total skin involvement. Pharmacokinetic assessment of topical drug products has previously been plagued by bioanalytical assay limitations and the lack of a standardized study design. Since the mid-1990's the US Food and Drug Administration has developed and implemented a pharmacokinetic maximal usage trial (MUsT) design to help address these issues. The MUsT design takes into account the following elements: the enrollment of patients rather than normal volunteers, the frequency of dosing, duration of dosing, use of highest proposed strength, total involved surface area to be treated at one time, amount applied per square centimeter, application method and site preparation, product formulation, and use of a sensitive bioanalytical method that has been properly validated. This paper provides a perspective of pre-MUsT study designs and a discussion of the individual elements that make up a MUsT.

KEYWORDS:

Absorption; Clinical Pharmacology; Dermatology; Maximal Use; Topical Drug Delivery

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center